MiMedx Group, Inc. announced the launch of AXIOFILL, an Extracellular Matrix (ECM) Particulate product derived from human placental tissue. AXIOFILL is the first and only human placental-derived particulate product available for Surgical Recovery procedures. The product offers a competitive advantage over other xenograft, or animal-based, particulate products that undergo aggressive processing techniques to eliminate potential antigens.

The existing market for xenograft products, including particulates, is estimated at $230 Million. AXIOFILL provides a cost-effective human collagen scaffold that is conducive for use in large, complex wounds and those of irregular geometries. It may be applied directly as a dry particulate, or with the addition of saline, as a paste depending upon surgeon preference and clinical need.

AXIOFILL is processed using a proprietary PURION technique that preserves the natural tissue microstructure. The resulting biocompatible scaffold retains key structural proteins, including type I and type IV collagen, laminin, and fibronectin.